As of 2026-09-27, the Relative Valuation of GT Biopharma Inc (GTBP) is (483.31) USD. This relative valuation is based on P/E multiples. With the latest stock price at 6.89 USD, the upside of GT Biopharma Inc based on Relative Valuation is -7114.6%.
The range of the Relative Valuation is (438.68) - (691.61) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 27.5x - 43.9x | 30.3x |
| Forward P/E multiples | 27.8x - 44.1x | 31.0x |
| Fair Price | (438.68) - (691.61) | (483.31) |
| Upside | -6467.0% - -10137.9% | -7114.6% |
| Date | P/E |
| 2026-09-25 | -0.44 |
| 2026-09-24 | -0.43 |
| 2026-09-23 | -0.45 |
| 2026-09-22 | -0.46 |
| 2026-09-21 | -0.46 |
| 2026-09-18 | -0.45 |
| 2026-09-17 | -0.47 |
| 2026-09-16 | -0.50 |
| 2026-09-15 | -0.57 |
| 2026-09-14 | -0.74 |
| 2026-09-11 | -0.55 |
| 2026-09-10 | -0.39 |
| 2026-09-09 | -0.38 |
| 2026-09-08 | -0.33 |
| 2026-09-04 | -0.38 |
| 2026-09-03 | -0.40 |
| 2026-09-02 | -0.45 |
| 2026-09-01 | -0.46 |
| 2026-08-31 | -0.45 |
| 2026-08-28 | -0.48 |
| 2026-08-27 | -0.48 |
| 2026-08-26 | -0.46 |
| 2026-08-25 | -0.47 |
| 2026-08-24 | -0.49 |
| 2026-08-21 | -0.46 |
| 2026-08-20 | -0.45 |
| 2026-08-19 | -0.45 |
| 2026-08-18 | -0.44 |
| 2026-08-17 | -0.45 |
| 2026-08-14 | -0.47 |
| 2026-08-13 | -0.47 |
| 2026-08-12 | -0.48 |
| 2026-08-11 | -0.50 |
| 2026-08-10 | -0.51 |
| 2026-08-07 | -0.51 |
| 2026-08-06 | -0.48 |
| 2026-08-05 | -0.50 |
| 2026-08-04 | -0.52 |
| 2026-08-03 | -0.49 |
| 2026-07-31 | -0.47 |
| 2026-07-30 | -0.49 |
| 2026-07-29 | -0.48 |
| 2026-07-28 | -0.50 |
| 2026-07-27 | -0.53 |
| 2026-07-24 | -0.51 |
| 2026-07-23 | -0.53 |
| 2026-07-22 | -0.55 |
| 2026-07-21 | -0.57 |
| 2026-07-20 | -0.54 |
| 2026-07-17 | -0.56 |